

(43) International Publication Date
11 September 2009 (11.09.2009)(10) International Publication Number
WO 2009/111337 A1

(51) International Patent Classification:

C07D 221/12 (2006.01) C07D 491/12 (2006.01)
C07D 471/04 (2006.01) C07D 495/04 (2006.01)
C07D 471/12 (2006.01) A61K 31/4375 (2006.01)
C07D 491/056 (2006.01) A61P 37/04 (2006.01)

(21) International Application Number:

PCT/US2009/035563

(22) International Filing Date:

27 February 2009 (27.02.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/033,139 3 March 2008 (03.03.2008) US
61/148,336 29 January 2009 (29.01.2009) US

(71) Applicants (for all designated States except US): **IRM LLC** [US/US]; 131 Front Street, P.O. Box 2899, HM LX Hamilton (BM). **NOVARTIS AG.** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WU, Tom Yao-Hsiang** [CA/US]; 9175 Judicial Drive, San Diego, CA

92122 (US). **LI, Yongkai** [CN/US]; 935 Babauta Road, Unit 7, San Diego, CA 92129 (US). **CORTEZ, Alex** [US/US]; 4073 Kendall Street, Apt.C, San Diego, CA 92109 (US). **ZOU, Yefen** [CN/US]; 3420 Lebon Drive, San Diego, CA 92122 (US). **MISHRA, Pranab** [US/US]; 11948-3 Cypress Canyon Road, San Diego, CA 92131 (US). **ZHANG, Xiaoyue** [CN/US]; 7698 Palmilla Drive, Apt. 1113, San Diego, CA 92122 (US). **SKIBINSKI, David** [GB/IT]; c/o Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, I-53100 Siena (IT). **SINGH, Manmohan** [US/US]; c/o Novartis Vaccines And Diagnostics, Inc., 4560 Horton Street, Emeryville, CA 94608 (US). **VALIANTE, Nicholas** [US/US]; c/o Novartis Vaccines And Diagnostics, Inc., 4560 Horton Street, Emeryville, CA 94608 (US).

(74) Agents: **RAYMOND, Daniel, E.** et al.; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,

[Continued on next page]

(54) Title: COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS





FIGURE 5

(57) Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X³ is N; X⁴ is N Or CR³; X⁵ is -CR⁴=CR⁵.



KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*